SIGA NASDAQ
Credit Risk of going bust: lower than 91% of companies Debt: 0.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), SIGA Technologies, Inc. would be worth roughly what it owes.
Total debt $439K against a stock market value of $226.7M.
Distance to default 14.38 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $220K (short-term plus half of long-term), stock volatility 47.8%; Altman Z 13.71. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
New York City, NY 10065
US
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Nabel Gary J. | M-Exempt | 24,116 | — | 2026-06-09 |
| Nabel Gary J. | D-Return | 7,235 | $4.39 | 2026-06-09 |
| Nabel Gary J. | M-Exempt | 24,116 | — | 2026-06-09 |
| Nabel Gary J. | A-Award | 34,169 | — | 2026-06-09 |
| KEANE JOHN M | M-Exempt | 24,116 | — | 2026-06-09 |